How Long After Wegovy Shot Do You Feel Side Effects?

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Side effects from a Wegovy injection are not usually a same-hour event, and the pharmacokinetics explain why. According to the Wegovy prescribing information, maximum plasma concentration of semaglutide is reached one to three days after a subcutaneous dose, and the elimination half-life is approximately one week — meaning semaglutide will be present in the circulation for about five to seven weeks after the last injectable dose. A medication that peaks days after the shot and lingers for weeks does not produce a neat, injection-timed reaction. What the labeling does say about timing is more useful and more specific: gastrointestinal adverse reactions "were most frequently reported during dosage escalation." The clock that matters is the escalation calendar, not the hour hand.

What the Pharmacokinetics Actually Predict

Because the half-life is roughly a week and doses are weekly, concentrations accumulate from one week to the next rather than rising and falling between injections. A person on a stable dosage is carrying a relatively steady level of drug, not a spike after each shot and a trough before the next.

The practical implication is that a symptom appearing three hours after the needle and one appearing three days later are equally consistent with the drug's behavior — and neither can be attributed to the injection itself with confidence. It also means that when a dosage level changes, the resulting shift in blood level takes weeks to fully express, and weeks to unwind.

The Timing the Label Does Describe

Wegovy labeling describes a dose escalation running through the first four months of injection treatment before the maintenance dosage is reached. It is against that structure that the adverse reaction statement should be read: gastrointestinal reactions were most frequently reported during dosage escalation.

That is a pattern measured in weeks. It tells you that the periods around dosage changes are when reports cluster, and that a steady maintenance period tends to be quieter than the climb. It does not promise that any individual will experience symptoms on a particular day, and the label does not assign a peak day to nausea or any other reaction.

What the Adverse Reaction Rates Look Like

Adverse reactions that occurred in at least 5 percent of patients treated with Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss.

In the adult trials, nausea was reported in 44 percent of Wegovy-treated patients versus 16 percent on placebo, diarrhea in 30 versus 16 percent, vomiting in 24 versus 6 percent, constipation in 24 versus 11 percent, abdominal pain in 20 versus 10 percent, and headache in 14 versus 10 percent. Severe gastrointestinal adverse reactions occurred in 4.1 percent of injection-treated adults versus 0.9 percent on placebo.

Note how much shows up in the placebo columns. A meaningful fraction of what people experience in the days after an injection is not attributable to the medication, which is one more reason single-episode timing is a poor diagnostic signal.

Severity and How Long Reactions Lasted

The pivotal 68-week trial reported in the New England Journal of Medicine, which enrolled 1,961 adults, described nausea and diarrhea as the most common adverse events with semaglutide and characterized them as typically transient, mild-to-moderate in severity, and subsiding with time. More participants on semaglutide than placebo discontinued because of gastrointestinal events, 4.5 percent versus 0.8 percent.

Labeling reports a comparable discontinuation picture: permanent discontinuation of Wegovy injection due to a gastrointestinal adverse reaction occurred in 4.3 percent of adults versus 0.7 percent on placebo, most often for nausea, vomiting and diarrhea. Read together, those figures describe reactions that were common, usually tolerable, and time-limited for the large majority — while being intolerable for roughly one in twenty-five.

Why the Mechanism Is Not a Post-Injection Surge

Semaglutide delays gastric emptying, and the label notes it is not recommended in patients with severe gastroparesis. Slowed gastric emptying is a continuous pharmacological effect present as long as drug levels are meaningful — not a burst that follows the needle.

That reframes the common experience of feeling worse after a particular meal. What people often perceive as a reaction to the shot is frequently the interaction between a persistently slowed stomach and meal size, fat content, or eating pace. Those are conversations worth having with your prescriber or a dietitian, because they are modifiable in a way that injection timing is not.

The Symptoms That Are Not About Timing at All

Some reactions in the labeling require attention whenever they appear, and the number of hours since the injection is irrelevant to them. Wegovy labeling carries warnings for acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis observed with GLP-1 receptor agonists, and for acute gallbladder disease, stating that treatment is associated with an increased occurrence of cholelithiasis and cholecystitis.

Severe or persistent abdominal pain, particularly pain radiating to the back, persistent vomiting, or signs of dehydration are not "waiting it out" situations. They warrant prompt medical evaluation. The full warnings and precautions section is longer than this article can responsibly summarize, and reading the Medication Guide that came with your prescription is the right move.

Your Timeline Belongs to Your Prescriber

Population incidence rates describe a group; they do not forecast an individual. Whether a symptom you are experiencing is expected, whether it warrants a change in plan, and what to do about it are clinical judgments that depend on your other medications, your history and your examination.

Compounded semaglutide adds one more variable. It is not an FDA-approved finished product, and the FDA does not review compounded preparations for safety, effectiveness or quality before marketing; it is prepared by a licensed pharmacy pursuant to a prescription for an individual patient. Wegovy and Ozempic are the approved semaglutide brands, and a compounded preparation is not a generic version of either. PlexusDx works only with licensed 503A compounding pharmacies, and every protocol is paired with clinician oversight so that side effect questions reach someone who can actually assess them.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How long after a Wegovy injection do side effects usually start?

The labeling does not assign an hour or a day. It does state that maximum plasma concentration of semaglutide is reached one to three days after a subcutaneous dose and that the elimination half-life is approximately one week, so levels accumulate week over week rather than spiking after each shot. The timing statement in the labeling is that gastrointestinal reactions were most frequently reported during dosage escalation.

Which side effects are most common with Wegovy?

In adult trials, nausea was reported in 44 percent of Wegovy-treated patients versus 16 percent on placebo, diarrhea in 30 versus 16 percent, vomiting in 24 versus 6 percent, constipation in 24 versus 11 percent, abdominal pain in 20 versus 10 percent, and headache in 14 versus 10 percent. Severe gastrointestinal adverse reactions occurred in 4.1 percent of injection-treated adults versus 0.9 percent on placebo.

Do the gastrointestinal effects go away?

In the pivotal 68-week trial of 1,961 adults, nausea and diarrhea were described as typically transient, mild-to-moderate in severity, and subsiding with time. They were not tolerable for everyone: 4.5 percent of semaglutide participants discontinued because of gastrointestinal events versus 0.8 percent on placebo, and labeling reports permanent discontinuation for a gastrointestinal reaction in 4.3 percent of adults versus 0.7 percent.

How long does semaglutide stay in the body after the last dose?

Labeling states that with an elimination half-life of approximately one week, semaglutide will be present in the circulation for about five to seven weeks after the last injectable dose. That is why side effects can persist after a dose is skipped or treatment is stopped, and why any change in a regimen takes weeks rather than days to fully express in blood levels.

When should side effects prompt urgent medical attention?

Regardless of how long it has been since an injection. Wegovy labeling carries warnings for acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis observed with GLP-1 receptor agonists, and for acute gallbladder disease, noting increased occurrence of cholelithiasis and cholecystitis. Severe or persistent abdominal pain, pain radiating to the back, persistent vomiting, or signs of dehydration warrant prompt evaluation.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.